Introduction: Metabolic liver steatosis is frequently associated with type 2 diabetes with an increased risk of progression to advanced fibrosis. Objective of this study was to estimate the prevalence of hepatic steatosis in patients with type 2 diabetes.
Methods: A cross-sectional study including 281 type 2 diabetic patients followed at the Department of Endocrinology in collaboration with the Hepato-Gastroenterology Department of Ibn Rochd University Hospital in Casablanca between January 2018 and September 2018. The HSI (Hepatic steatosis index) score was calculated for all patients according to the following formula: (8×ALT/AST) + BMI +2 (if type 2 diabetes) +2 (if female). An HSI> 36 score predicted the presence of hepatic steatosis. The variables studied were anthropometric, biological, HSI and hepatic ultrasound. Analyzes were performed by SPSS 25.
Results: Mean age of our patients was 54.15±13.45 years (2780) with a female predominance (76% of cases), a sex ratio of 3.25. Mean duration of diabetes was 10.5±8.5 years with an average glycated hemoglobin level of 10.2%. BMI was 29.9 kg / m SD2 and the average waist circumference was 110 cm. 38.8% of the patients were hypertensive, 58% were dyslipidemic, 7% were smokers and only 1.4% were ethyl (<20 g/d). Metabolic liver steatosis prevalence was 48% based on the HSI> 36 score. This prevalence is consistent with the results of hepatic ultrasound (42% of cases). Transaminase abnormalities were only seen in 6% of patients. Hepatic steatosis was significantly correlated with metabolic syndrome (<0.05). In multivariate analysis, the most predominant factor associated with hepatic steatosis was hypertriglyceridemia.
Conclusion: Non-invasive score (HSI) and hepatic ultrasound are easy tools for screening for fatty liver. A normal transaminase level in the diabetic does not eliminate the presence of fatty liver.
18 - 21 May 2019
European Society of Endocrinology